ZPBP抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Human testis tissue lysate, Primary antibody: P09252(ZPBP Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P09252(ZPBP Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P09252(ZPBP Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

Zona Pellucida Binding Protein (ZPBP) antibodies are primarily associated with research in reproductive biology and infertility. ZPBP, a sperm-specific protein localized in the acrosome, plays a critical role in sperm-egg interaction by mediating binding to the zona pellucida (ZP), the glycoprotein matrix surrounding mammalian oocytes. This interaction is essential for successful fertilization, as ZPBP facilitates sperm penetration through the ZP via acrosome reaction initiation.

Studies suggest that ZPBP antibodies may arise in autoimmune contexts or due to disrupted immune tolerance, potentially impairing fertility. In clinical settings, detecting ZPBP antibodies has been explored as a biomarker for diagnosing immune-related infertility, particularly in cases where conventional tests fail to identify causes. Animal models, notably mice, have shown that ZPBP dysfunction or antibody interference leads to reduced sperm-ZP binding and fertilization rates, underscoring its functional importance.

Research also investigates ZPBP's structural domains and antigenic epitopes to develop contraceptive vaccines or therapeutic strategies targeting sperm-egg fusion. However, human data remain limited, and the clinical relevance of ZPBP antibodies requires further validation. Current efforts focus on elucidating their role in unexplained infertility and refining assay specificity to distinguish pathological antibodies from benign immune responses.